We are live on ! Find out more
NWBOW

Northwest Biotherapeutics, Inc.
NWBOW

Delisted

NWBOW was delisted on the 16th of December, 2016.

Back to rankings

4 hedge funds and large institutions have $334K invested in Northwest Biotherapeutics, Inc. in 2014 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 4 → 4 (0)

0% more first-time investments, than exits

New positions opened: 1 | Existing positions closed: 1

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

27% less capital invested

Capital invested by funds: $455K → $334K (-$121K)

Holders
4
Holders Change
–
Holders Change %
0%
% of All Funds
0.11%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
U
UBS
Switzerland
+$10.2K

Top Sellers

Rank Fund Capital Flow
1
Allianz Asset Management
Allianz Asset Management
Germany
-$33.4K
Name Holding Trade Value Shares
Change 		Change in
Stake
Allianz Asset Management
1
Allianz Asset Management
Germany
$310K -$33.4K -8,430 -9%
AIG
2
American International Group
New York
$13.3K – – –
U
3
UBS
Switzerland
$10K +$10.2K +2,574 +1,629%
GSC
4
Ground Swell Capital
South Carolina
$1K +$788 +199 New

NWBOW Hedge Fund Activity: Q2 2014 in Review

4 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Northwest Biotherapeutics, Inc. (NWBOW) for Q2 2014, worth a combined $334K — down 27% from $455K a quarter earlier.

Fund positioning in NWBOW was balanced in Q2 2014: 1 fund opened new positions, 1 closed out, 1 added to existing stakes and 1 trimmed.

The largest buyer was UBS, adding an estimated $10.2K. The largest seller was Allianz Asset Management, cutting an estimated $33.4K.

  • 4 institutional investors held Northwest Biotherapeutics, Inc. (NWBOW) as of Q2 2014, unchanged from Q1 2014.
  • Funds reported $334K of Northwest Biotherapeutics, Inc. stock for Q2 2014, down 27% quarter-over-quarter.
  • 1 fund opened new Northwest Biotherapeutics, Inc. positions in Q2 2014 and 1 closed out, a net change of 0 holders.
  • The largest Northwest Biotherapeutics, Inc. buyer in Q2 2014 was UBS, an estimated $10.2K added.
  • The largest Northwest Biotherapeutics, Inc. seller in Q2 2014 was Allianz Asset Management, an estimated $33.4K sold.

Based on aggregated 13F filings for Q2 2014.